Clinical Trial Update: Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating allogeneic Epstein-Barr Virus-specific cytotoxic T-lymphocytes in patients with progressive, relapsed, or refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Allogeneic Epstein-Barr Virus-Specific Cytotoxic T-Lymphocytes

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Lymphoma | Phase 1 | Status: UNKNOWN